Abstract Purpose of Review To review the recent available evidence on epidemiology,
pathogenesis, clinical phenotypes, and management of antiphospholipid syndrome (APS) …

Antiphospholipid syndrome (APS) consists of thrombotic, non-thrombotic and obstetric
clinical manifestations develo** in individuals with persistent antiphospholipid antibodies …

Иммуновоспалительные (аутоиммунные и аутовоспалительные) ревматические
заболевания-не только весьма распространенные и тяжелые хронические …

To evaluate the safety and tolerability of belimumab given for 24 months in patients
persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable …

Background β2-glycoprotein I (β2GPI) complexed with human leukocyte antigen DR
(β2GPI/HLA-DR) was found to be a major autoantibody target in antiphospholipid syndrome …

Introduction Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS)
represents a challenging SLE endotype whose molecular basis remains unknown. Methods …

Introduction While the type I interferon (IFN-I) pathway is crucial in autoimmunity, its role in
antiphospholipid antibody (aPL)-positive subjects, including aPL carriers and …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by an
overproduction of cytokines, such as interleukins and interferons, contributing to systemic …

Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or
morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity …

Immune-inflammatory (autoimmune and autoinflammatory) rheumatic diseases are
widespread severe chronic inflammatory diseases and also “models” for studying the …